Tag: JNJ
-
An Update on the 2026 Dogs of the Dow Strategy
The Dogs of the Dow are proving their value in 2026, with several of this year’s top-yielding Dow components already posting impressive gains.
-
JNJ Stock Slides After Guidance Raise: Know What You Own, Buy the Dip
Johnson & Johnson is a dividend king with a growing business and a growing payout. This pullback looks like a buying opportunity for JNJ stock.
-
An Update on the 2026 Dogs of the Dow Strategy
For investors looking to build wealth with blue-chip dividend stocks, few strategies have stood the test of time like the Dogs of the Dow.
-
3 Income ETFs to Help Build a More Resilient Portfolio in a Crazed Market
Investors looking for alternatives to the hottest growth stocks can consider income ETFs that combine dividends, value exposure, and relatively low costs.
-
4 Income ETFs That Could Help Investors Navigate Market Volatility
Consider these four income ETFs to help diversify and safeguard your portfolio from market volatility.
-
3 High-Yield Dividend ETFs to Protect Your Portfolio
In times of chaos, dividend ETFs can offer investors a compelling mix of stability, passive income, and long-term growth.
-
Johnson & Johnson Is Proving To Be Less Dependent On Patent Cliffs
Johnson & Johnson beat earnings and raised guidance, showing its diversified business is becoming less dependent on blockbuster drug patents.
-
Dogs of the Dow 2026: One of the Best Investment Strategies
The Dogs of the Dow are off to another strong year. See why this time-tested dividend strategy continues to reward long-term investors.
-
3 Top Dividend ETFs to Buy for Income, Stability, and Long-Term Growth
Looking for income and stability? These three dividend ETFs offer reliable yields, quality holdings, and long-term growth potential.
-
AbbVie vs. JNJ: Which Biopharma Stock Wins in 2026?
Biopharma stocks may benefit from sector rotation. AbbVie and Johnson & Johnson deserve a close look, but they are not the same trade.